FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
- Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD
Heidelberg, Germany – 17 February 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces its recognition as one of twelve leading companies selected to present at the prestigious Bio-Neuroscience Conference, the premier global gathering of neuroscience innovation leaders, investors, and pharmaceutical executives. This event will take place from February 24–26, 2026, in Amsterdam, The Netherlands, showcasing organizations that demonstrate excellence and leadership in neuroscience research and therapeutic innovation.
